麻豆果冻传媒影音

Phase II data presented at December's American Society of Hematology (ASH) virtual meeting showed increased stringent CR and MDR rates when adding daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) for transplant-eligible myeloma patients.

In this exclusive MedPage Today video, , of Moffitt Cancer Center in Tampa, Florida, talks about the promising , and whether or not the four-drug combination should be the new standard of care.

Following is a transcript of his remarks:

Updates this year to ASH, we were looking at what happens with the addition of Darzalex to maintenance therapy. So think about it as induction transplant consolidation of the maintenance as critical parts of therapies. This is really focusing on what the Darzalex addition to the standard-of-care maintenance had done. And really in the end, what we show is a significant increase in a number of the critical end points here. We know that one, the RVd followed by D-R maintenance significantly improved response rates and depth of response. That means sCR rates, that means MRD rates, versus RVd standard and R maintenance, again with transplant and consolidation in there as well. We also know that the addition of Darzalex to Revlimid maintenance in and of itself improves the depth of response, such as in sCR rates, as well as MRD rates after transplant consolidation.

So in the end, very promising with the addition of Darzalex added to this standard of care regimen. We know that the progression free survival again is improved, and we're going to continue to see how these data mature over time and see how this affects overall survival. We know that these data are exciting and really, to our collectiveness it sounds like this D-RVd should be considered a candidate as a potential new standard-of-care for our transplant eligible most moderate patients. And we know that there's an ongoing, head-to-head phase III study called the PERSEUS study, which is out there trying to address this question to a greater degree.

I think to put in the context of other studies that have been done as well, we know that in transplant ineligible patients, the addition of Darzalex does markedly improve outcomes when added to standard-of-care as with D-RD as well as D-VMP. And obviously, nice phase III data from the CASSIOPEIA data looked at Darzalex plus VTD, and also demonstrated improved PFS and met that primary endpoint. So again, in the context of that, this really does suggest that this quad or four-drug regimen really should be considered as a potential new standard of care for transplant-eligible multiple myeloma patients.

Comment